Company news
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H (HKEX:6990) news
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H news releases on 6ix. Latest, Oct 2, 2026: Monthly Return of Equity Issuer on Movements…
View Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H →
Press releases & updates
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session
September 22, 2026
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
September 14, 2026
Kelun-Biotech Announces 2026 Interim Results
August 17, 2026
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
July 30, 2026
Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
July 27, 2026
Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
July 15, 2026
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
July 14, 2026
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
June 1, 2026
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
May 30, 2026
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
May 28, 2026
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
May 28, 2026
Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
May 21, 2026
Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
May 11, 2026
The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
May 8, 2026
Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
April 21, 2026
Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
April 12, 2026
Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development
April 9, 2026
Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC
March 24, 2026
KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
March 23, 2026
Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
March 21, 2026
Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
March 18, 2026
Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis
March 9, 2026
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 26, 2026
Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
February 6, 2026
Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference
January 15, 2026
Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
January 5, 2026
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
January 5, 2026
Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
January 5, 2026
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
December 4, 2025
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
November 27, 2025
/C O R R E C T I O N -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./
November 26, 2025
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
November 24, 2025
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
November 9, 2025
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
October 20, 2025
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
October 19, 2025
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
October 18, 2025
Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
October 17, 2025
Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy
October 11, 2025
Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
September 23, 2025
Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
September 22, 2025
Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC
August 19, 2025
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
August 18, 2025
Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378
July 23, 2025
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
June 10, 2025
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
June 6, 2025
Kelun-Biotech Announces Approximately US$250 Million Placement
June 5, 2025
Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting
May 23, 2025
Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation
May 21, 2025
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
April 24, 2025